# Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring a 112% Potential Upside in Biotech

- Link: https://www.directorstalkinterviews.com/viking-therapeutics-inc-vktx-stock-analysis-exploring-a-112-potential-upside-in-biotech/4121212608
- Published: 2025-08-19T10:05:48+01:00
- Author: Madison Wilson

Viking Therapeutics, Inc. (NASDAQ: VKTX) has been catching the eyes of investors
in the healthcare sector, particularly within the biotechnology industry. With a
market capitalization of $4.73 billion, this U.S.-based clinical-stage biopharmaceutical
company is making significant strides in developing novel therapies for metabolic
and endocrine disorders. The company’s lead product, VK2809, is a promising treatment
undergoing Phase IIb clinical trials for non-alcoholic steatohepatitis (NASH) and
non-alcoholic fatty liver disease (NAFLD).

Currently trading at $42.09, Viking Therapeutics has experienced a substantial price
range over the past year, fluctuating between $19.98 and $78.03. Despite a modest
recent price change of 0.05%, the company has garnered considerable attention due
to its impressive potential upside. With an average target price of $89.28, analysts
forecast a potential upside of 112.11%, making it an attractive prospect for risk-
tolerant investors.

Viking Therapeutics stands out due to its robust pipeline, which includes VK5211
for hip fracture recovery, VK0612 for type 2 diabetes, VK2735 as a dual agonist 
for metabolic disorders, and VK0214 for X-linked adrenoleukodystrophy. These innovative
treatments underscore the company’s commitment to addressing unmet medical needs
in metabolic and endocrine disorders.

However, investors should note that Viking Therapeutics is still in the clinical
stage, which means it currently lacks revenue and net income, as indicated by its
negative EPS of -1.54 and a concerning return on equity of -19.99%. The company’s
free cash flow is also negative at -$102.1 million, which is not uncommon for biotech
firms in this phase as they heavily invest in research and development.

Interestingly, Viking Therapeutics has received strong support from analysts, with
16 buy ratings and only 2 hold ratings, and no sell ratings. This bullish sentiment
is further emphasized by the wide target price range of $33.00 to $125.00, reflecting
the high expectations for the company’s drug candidates.

From a technical perspective, the stock’s relative strength index (RSI) sits at 
22.33, suggesting that it is currently oversold. Its moving averages, with a 50-
day at $31.41 and a 200-day at $34.99, indicate that the stock is trading above 
both averages, which could be a signal of potential upward momentum if the company’s
clinical trials yield positive results.

For investors seeking exposure to the biotechnology sector, Viking Therapeutics 
presents an intriguing opportunity, albeit with the typical risks associated with
clinical-stage biopharmaceutical companies. As the company continues to advance 
its pipeline, the potential for significant growth remains, but investors should
remain vigilant and consider the inherent volatility and risks of investing in biotech
stocks.

Share on: